

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

3DMed

思路迪

3D Medicines Inc.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

INSIDE INFORMATION IN RELATION TO ARBITRATION PROCEEDINGS

The announcement is made by the Company pursuant to Rule 13.09(2)(a) of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

In December 2020, the Company and SELLAS Life Sciences Group, Inc., a company listed on the Nasdaq Stock Market (stock code: SLS) (“**SELLAS**”) entered into an exclusive license agreement (the “**Exclusive License Agreement**”) regarding the development and commercialization of 3D189 (also known as galinpepimut-S, “**GPS**”) as well as 3D059 (also known as heptavalent galinpepimut-S, “**GPS+**”) in mainland China, Hong Kong, Macau and Taiwan (collectively, the “**Territory**”). The Exclusive License Agreement was further supplemented by a side letter agreement dated November 23, 2022 and an addendum to the side letter dated May 5, 2023 (collectively, the “**Agreements**”). For further details on the Exclusive License Agreement, please refer to the prospectus of the Company dated 29 November 2022.

The Company has received a notice of arbitration dated December 20, 2023 (the “**Notice**”) filed by SELLAS and its subsidiary, SLSG Limited, LLC (collectively, the “**Claimants**”) with the Hong Kong International Arbitration Centre against the Company as respondent, alleging certain disputes arising from the Agreements, including, among other things, the trigger and payment of the milestone payments relating to initiation of the phase III clinical trials for 3D189.

The Board considers that the claims and allegations from the Claimants are groundless and unjustified, and that the Company does not owe any liability to the Claimants and is seeking legal advice in respect of the Notice. The Company will strenuously contest the arbitration. The Company finds the circumstances regrettable and reserves all rights, including the right to counterclaim or seek any other remedy against SELLAS in the arbitration.

The Board is presently unable to assess the potential impact of the arbitration, if any, on the Group at this stage. The Company is committed to developing all drug candidates in its pipeline in accordance with its research and development progress, while ensuring compliance with its contractual and regulatory requirements.

The Company will make further announcement(s) to update the Shareholders and the public as required under the Listing Rules as and when appropriate.

Shareholders and public investors are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong
December 27, 2023

As at the date of this announcement, the Board comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.